STAT+: Pharmalittle: An emerging star in biotech investment; U.S. government expected to stop paying for Covid shots next year

Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m picking up the baton from Allison as we continue to fill in for Ed this week. I’m not a coffee drinker, but I’ve poured myself a cup of water. No ice, though, as I find it dilutes the flavor. Jokes aside, here are some newsy items for you to peruse this morning.

Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight, according to STAT. Over the last five years, the venture capital firm, whose parent company manages $280 billion from the United Arab Emirates’ vast oil business, has risen from obscurity and earned the respect of observers who say it could be the next potential breakout star in the investment world.

Continue to STAT+ to read the full story…